ExodusPoint Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

ExodusPoint Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.4M	Sell	202,116 -27,010	-12%	-$1.38M	0.08%	220
2025 Q4	$11.4M	Buy	+229,126	New	+$11.1M	0.09%	225
2023 Q2	–	Sell	-47,421	Closed	-$1.72M	–	2233
2023 Q1	$1.72M	Buy	+47,421	New	+$1.82M	0.01%	947
2022 Q2	–	Sell	-33,343	Closed	-$1.08M	–	2431
2022 Q1	$1.08M	Sell	33,343 -2,527	-7%	-$77.5K	0.01%	1098
2021 Q4	$1.05M	Buy	+35,870	New	+$1.09M	0.01%	1045

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ExodusPoint Capital Management's SUPN Position: Q1 2026 in Review

ExodusPoint Capital Management reduced its Supernus Pharmaceuticals (SUPN) stake by 12% in Q1 2026, selling an estimated $1.38M and leaving 202,116 shares worth $10.4M. The position accounts for 0.08% of the portfolio, ranked #220.

ExodusPoint Capital Management first reported a position in SUPN in Q4 2021 and has held it in 5 quarters since. The position peaked at $11.4M in Q4 2025. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

ExodusPoint Capital Management held 202,116 shares of Supernus Pharmaceuticals worth $10.4M as of Q1 2026.
ExodusPoint Capital Management sold 27,010 Supernus Pharmaceuticals shares in Q1 2026, an estimated $1.38M.
Supernus Pharmaceuticals made up 0.08% of ExodusPoint Capital Management's portfolio in Q1 2026, its #220 holding.
ExodusPoint Capital Management first reported a position in Supernus Pharmaceuticals in Q4 2021 and has held it in 5 quarters since.
ExodusPoint Capital Management's Supernus Pharmaceuticals position peaked at $11.4M in Q4 2025.
327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.